Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adicet Bio, Inc.TORC · Entity 6860 | Director | June 03, 2020 | June 05, 2020 |
| Amylyx Pharmaceuticals, Inc.AMLX · Entity 259 | Director | June 04, 2026 | June 08, 2026 |
| Apnimed, Inc.APMD · Entity 4910 | Director | July 30, 2026 | August 03, 2026 |
| COVETRUS, INC.CVET · Entity 123087 | Director | October 13, 2022 | October 13, 2022 |
| GELESIS HOLDINGS, INC.GLS · Entity 109516 | Director | May 06, 2022 | May 09, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adicet Bio, Inc.
Report date June 03, 2020 · Filed June 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2030-06-02 | Direct | 14,414 |
Reported balance
After 2020-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-06-03 · Grant · Acquired 14,414 · Balance 14,414 F1: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 3, 2020 with respect to 14,414 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.
Amylyx Pharmaceuticals, Inc.
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.31 · Expires 2036-06-03 | Direct | 24,372 |
Reported balance
After 2026-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 24,372 · Balance 24,372 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Apnimed, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2033-09-18 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Disposition to issuer · Disposed 51,890 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.00 · Expires 2033-09-18 | Direct | 51,890 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 51,890 · Balance 51,890 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-07-07 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-03 · Disposition to issuer · Disposed 44,477 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-07-07 | Direct | 44,477 |
Reported balance
After 2026-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 44,477 |
Reported balance
After 2026-07-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-30 · Grant · Acquired 44,477 · Balance 44,477 F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-03 · Disposition to issuer · Disposed 44,477 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 44,477 |
Reported balance
After 2026-08-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-03 · Grant · Acquired 44,477 · Balance 44,477 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F4: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
COVETRUS, INC.
Report date October 13, 2022 · Filed October 13, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-10-13 transaction · row 1
1 source rowRow 1 · 2022-10-13 · Disposition to issuer · Disposed 13,275 · Balance 0 F1: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2022-10-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-10-13 · Disposition to issuer · Disposed 14,638 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F3: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration").
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof.
F3: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration.
GELESIS HOLDINGS, INC.
Report date May 06, 2022 · Filed May 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,832 |
Reported balance
After 2022-05-06 transaction · row 1
1 source rowRow 1 · 2022-05-06 · Grant · Acquired 53,832 · Balance 53,832 F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F2: These RSUs vest in full on March 3, 2023, subject to the reporting person's continued service at such time. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement.
F2: These RSUs vest in full on March 3, 2023, subject to the reporting person's continued service at such time.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 14,676 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 9,452 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Apellis Pharmaceuticals, Inc.
Report date May 14, 2026 · Filed May 14, 2026
Section 16 reporting ended · disclosed 2026-05-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-14 · Other · Disposed 30,666 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"), F2: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, F3: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-05-14 · Disposition to issuer · Disposed 3,062 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2026-05-14 · Disposition to issuer · Disposed 5,744 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 4
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 4 · 2026-05-14 · Disposition to issuer · Disposed 7,961 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 5
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 5 · 2026-05-14 · Disposition to issuer · Disposed 3,544 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 6
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 6 · 2026-05-14 · Disposition to issuer · Disposed 3,877 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $25.12 | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-05-14 · Disposition to issuer · Disposed 14,684 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.13 | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-05-14 · Disposition to issuer · Disposed 37,500 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.91 | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-05-14 · Disposition to issuer · Disposed 11,199 · Balance 0 F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $47.28 | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-05-14 · Disposition to issuer · Disposed 8,554 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $51.71 | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-05-14 · Disposition to issuer · Disposed 7,441 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $57.20 | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-05-14 · Disposition to issuer · Disposed 27,600 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $59.86 | Direct | 0 |
Reported balance
After 2026-05-14 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-05-14 · Disposition to issuer · Disposed 5,748 · Balance 0 F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"),
F2: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions,
F3: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes.
F4: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award.
F5: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement.
F6: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option.
F7: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 7 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,477 Underlying: Common Stock · 44,477 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 6 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 44,477 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 4 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,477 Underlying: Common Stock · 44,477 shares Expires 2036-07-07 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 3 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 44,477 shares Expires 2036-07-07 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F3 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after July 7, 2026, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 51,890 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,890 Underlying: Common Stock · 51,890 shares Expires 2033-09-18 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 51,890 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 51,890 shares Expires 2033-09-18 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after September 18, 2023, and the remainder of the shares vest and become exercisable in substantially equal quarterly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 30, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 44,477 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330508 · ownership.xml · derivative · entry 5 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,477 Underlying: Class A Common Stock · 44,477 shares Expires 2036-07-29 F4 · derivative.exercise_date: The shares subject to such option vest and become exercisable in substantially equal monthly installments for a period of 36 months after July 30, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:00 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 24,372 | $0.00 Strike: $14.31 | $0.00 |
DisclosureSEC source: 0001193125-26-261637 · ownership.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,372 Underlying: Common Stock · 24,372 shares Expires 2036-06-03 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2027 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerStock Option (right to buy) · Derivative | 5,748 | Not disclosed Strike: $59.86 | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 13 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,748 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerStock Option (right to buy) · Derivative | 27,600 | Not disclosed Strike: $57.20 | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 12 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,600 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerStock Option (right to buy) · Derivative | 7,441 | Not disclosed Strike: $51.71 | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 11 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,441 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerStock Option (right to buy) · Derivative | 8,554 | Not disclosed Strike: $47.28 | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 10 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,554 shares Expires not disclosed F7 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. F7 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. F7 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each vested or unvested option with an exercise price per share that was equal to or greater than $45.00 (the Aggregate Amount) was cancelled without consideration and will have no further force or effect. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerStock Option (right to buy) · Derivative | 11,199 | Not disclosed Strike: $31.91 | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 9 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,199 shares Expires not disclosed F6 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerStock Option (right to buy) · Derivative | 37,500 | Not disclosed Strike: $26.13 | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 8 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,500 shares Expires not disclosed F6 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerStock Option (right to buy) · Derivative | 14,684 | Not disclosed Strike: $25.12 | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · derivative · entry 7 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,684 shares Expires not disclosed F6 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. F6 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. F6 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each outstanding and unexercised option to purchase shares of Common Stock that was vested pursuant to its existing terms or that vested as a result of the transactions contemplated by the Merger Agreement (each, a "Cash-Out Option") and had an exercise price per share that was less than $41.00 (the Cash Amount) was automatically cancelled and converted into the right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such option, multiplied by (y) the excess of the Cash Amount over the exercise price per share of such option and (ii) one CVR for each share of Common Stock underlying such option. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerCommon Stock | 3,877 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 6 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerCommon Stock | 3,544 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 5 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerCommon Stock | 7,961 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 4 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerCommon Stock | 5,744 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 3 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | Disposition to issuerCommon Stock | 3,062 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F4 · price: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · price: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. F4 · balance_after: Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each Converted RSU Award that was subject solely to a time-based vesting schedule (including, for the avoidance of doubt, any Converted RSU Award for which the performance period of any applicable performance metric had already ended) was automatically cancelled and converted into the contingent right to receive (i) an amount of cash, without interest and less applicable tax withholding, equal to the product of (x) the total number of shares of Common Stock underlying such Converted RSU Award multiplied by (y) the Cash Amount and (ii) one CVR for each share of Common Stock underlying such Converted RSU Award. F5 · balance_after: (continued from footnote 4) Subject to the holder's continued service through the vesting dates applicable to the Converted RSU Award under its terms as in effect immediately prior to the Effective Time, all payments in respect of such Converted RSU Award pursuant to the Merger Agreement will vest and become payable at the same time as the underlying Converted RSU Award would have vested and become settled pursuant to its terms and shall otherwise remain subject to the same terms and conditions (including any "double-trigger" vesting provisions applicable to the Converted RSU Award immediately prior to the Effective Time, as extended as provided by the Merger Agreement) as were applicable to the underlying RSU immediately prior to the Effective Time and the terms of the CVR Agreement. Read SEC document |
| May 14, 2026 Filed May 14, 2026 23:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | OtherCommon Stock | 30,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-224618 · ownership.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"), F2 · kind: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, F3 · kind: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes. F1 · price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among Apellis Pharmaceuticals, Inc. (the "Issuer"), Biogen Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Aspen Purchaser Sub, Inc. ("Purchaser"), dated as of March 31, 2026, the shares of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the tender offer were exchanged for: (i) $41.00 per share of Common Stock, net to the seller in cash, without interest and subject to reduction for any applicable tax withholding (the "Cash Amount"), plus (ii) one contractual, non-transferable contingent value right per share of Common Stock (each, a "CVR"), F2 · price: (continued from footnote 1) which entitles the holder to receive potential payments of up to an aggregate of $4.00 in cash, without interest and subject to reduction for any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and conditions of a contingent value rights agreement (the "CVR Agreement" and the Cash Amount plus one CVR, together, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of the filing and acceptance of the certificate of merger relating thereto on May 14, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation (the "Surviving Corporation") and a wholly owned subsidiary of Parent. In the Merger, each share of Common Stock issued and outstanding immediately prior to the Effective Time, subject to certain exceptions, F3 · price: (continued from footnote 2) was automatically converted into the right to receive the Offer Price from Purchaser, without interest and subject to reduction for any applicable withholding taxes. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:36 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantStock Option (Right to Buy) · Derivative | 14,684 | $0.00 Strike: $25.12 | $0.00 |
DisclosureSEC source: 0001492422-26-000010 · form4.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,684 Underlying: Common Stock · 14,684 shares Expires 2033-12-31 F2 · derivative.exercise_date: This option was granted on January 1, 2026. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant. Read SEC document |
| January 01, 2026 Filed Jan 5, 2026 21:36 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantCommon Stock | 7,961 | $0.00 | $0.00 |
DisclosureSEC source: 0001492422-26-000010 · form4.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,666 F1 · kind: This restricted stock unit was granted on January 1, 2026. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:12 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.05 | $0.00 |
DisclosureSEC source: 0000950170-25-083734 · ownership.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2026 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:19 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantStock Option (Right to Buy) · Derivative | 11,199 | $0.00 Strike: $31.91 | $0.00 |
DisclosureSEC source: 0001127602-25-000425 · form4.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,199 Underlying: Common Stock · 11,199 shares Expires 2032-12-31 F2 · derivative.exercise_date: This option was granted on January 1, 2025. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 21:19 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantCommon Stock | 6,267 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-000425 · form4.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,705 F1 · kind: This restricted stock unit was granted on January 1, 2025. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 20:52 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0000950170-24-070811 · ownership.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 6, 2025 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 01, 2024 Filed Jan 2, 2024 21:13 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantStock Option (Right to Buy) · Derivative | 5,748 | $59.86 Strike: $59.86 | $344,075.28 |
DisclosureSEC source: 0001127602-24-000120 · form4.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,748 Underlying: Common Stock · 5,748 shares Expires 2030-12-31 F2 · derivative.exercise_date: This option was granted on January 1, 2024. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant. Read SEC document |
| January 01, 2024 Filed Jan 2, 2024 21:13 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantCommon Stock | 3,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-000120 · form4.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,438 F1 · kind: This restricted stock unit was granted on January 1, 2024. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 23:34 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (right to buy) · Derivative | 16,985 | $0.00 Strike: $26.25 | $0.00 |
DisclosureSEC source: 0000899243-23-015406 · doc4.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,985 Underlying: Common Stock · 16,985 shares Expires 2033-06-08 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 8, 2024 or (ii) the date of the next annual meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantStock Option (Right to Buy) · Derivative | 7,441 | $0.00 Strike: $51.71 | $0.00 |
DisclosureSEC source: 0000899243-23-000668 · doc4.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,441 Underlying: Common Stock · 7,441 shares Expires 2030-12-31 F2 · derivative.exercise_date: This option was granted on January 1, 2023. The option vests quarterly on the last day of each quarter from the date of grant, subject to his continued service as a director and expires seven years after the date of grant. Read SEC document |
| January 01, 2023 Filed Jan 4, 2023 22:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantCommon Stock | 3,867 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-000668 · doc4.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,097 F1 · kind: This restricted stock unit was granted on January 1, 2023. The restricted stock unit will fully vest on the first anniversary of the date of grant, subject to his continued service as a director, or upon later termination of his service as a director at his election. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 15:03 UTC | COVETRUS, INC. CVET · Entity 123087 | Disposition to issuerRestricted Stock Units · Derivative | 14,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-22-000143 · wf-form4_166567340597921.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,638 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, outstanding RSUs vested (to the extent unvested) and were terminated and cancelled in exchange for the right to receive a lump sum cash payment equal to (x) the number of Shares underlying such RSUs immediately prior to the effective time of the Merger, multiplied by (y) the Merger Consideration. Read SEC document |
| October 13, 2022 Filed Oct 13, 2022 15:03 UTC | COVETRUS, INC. CVET · Entity 123087 | Disposition to issuerCommon Stock | 13,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-22-000143 · wf-form4_166567340597921.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: In connection with the merger of Corgi Merger Sub, Inc. ("Merger Sub") with and into the Issuer (the "Merger") pursuant to that certain Agreement and Plan of Merger, dated as of May 24, 2022, as amended from time to time, by and among the Issuer, Corgi Bidco, Inc. and Merger Sub, Inc. ("Merger Agreement"), shares of common stock, par value $0.01 per share, of the Issuer (the "Shares" and each a "Share"), were converted into the right to receive $21.00 per Share in cash, without interest (the "Merger Consideration"). Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:06 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionRestricted Stock Units · Derivative | 8,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-22-000098 · wf-form4_165713799617599.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,275 shares Expires 2022-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:06 UTC | COVETRUS, INC. CVET · Entity 123087 | Exercise / conversionCommon Stock | 8,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-22-000098 · wf-form4_165713799617599.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 20:05 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 19,000 | $0.00 Strike: $13.56 | $0.00 |
DisclosureSEC source: 0000899243-22-021890 · doc4.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: This option shall vest in full upon the earlier of (i) June 9, 2023 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. Read SEC document |
| May 11, 2022 Filed May 13, 2022 20:10 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantRestricted Stock Units · Derivative | 14,638 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-22-000071 · wf-form4_165247260944118.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,638 Underlying: Common Stock · 14,638 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date. F2 · derivative.expiration_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date. Read SEC document |
| May 06, 2022 Filed May 9, 2022 16:17 UTC | GELESIS HOLDINGS, INC. GLS · Entity 109516 | GrantCommon Stock | 53,832 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-057532 · tm2214815d6_4seq1.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,832 F1 · kind: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. F2 · shares: These RSUs vest in full on March 3, 2023, subject to the reporting person's continued service at such time. F1 · price: Represents a grant of restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's common stock upon vesting and settlement. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:37 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | GrantStock Option (Right to Buy) · Derivative | 8,400 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-22-001527 · doc4.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 Underlying: Common Stock · 8,400 shares Expires 2032-01-06 F1 · derivative.exercise_date: This option shall vest in full on the date of the Corporation's 2022 Annual Stockholders Meeting, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| January 06, 2022 Filed Jan 11, 2022 01:37 UTC | Amylyx Pharmaceuticals, Inc. AMLX · Entity 259 | PurchaseCommon Stock | 3,947 | $19.00 | $74,993.00 |
DisclosureSEC source: 0000899243-22-001527 · doc4.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,947 Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:28 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantStock Option (Right to Buy) · Derivative | 8,554 | $0.00 Strike: $47.28 | $0.00 |
DisclosureSEC source: 0001127602-22-000726 · form4.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,554 Underlying: Common Stock · 8,554 shares Expires 2029-12-31 F2 · derivative.exercise_date: This represents a non-qualified stock option grant made on 1/1/2022 that vests quarterly over 1 year from the date of grant, subject to continued service as a director, and expires seven years from the date of grant. Read SEC document |
| January 01, 2022 Filed Jan 5, 2022 02:28 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantCommon Stock | 4,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-000726 · form4.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,230 F1 · kind: This represents a restricted stock unit grant made on 1/1/2022 that fully vest on the first anniversary of the date of grant, subject to continued service as a director. Read SEC document |
| August 10, 2021 Filed Aug 11, 2021 20:09 UTC | COVETRUS, INC. CVET · Entity 123087 | PurchaseCommon Stock | 5,000 | $23.24 | $116,200.00 |
DisclosureSEC source: 0001752836-21-000236 · wf-form4_162871252039507.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: Price reported constitutes the average weighted price of shares purchased. Shares were purchased at varying prices in the range of $23.05 - $23.37. The Reporting Person hereby undertakes, upon request by the Commission staff, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 20:03 UTC | COVETRUS, INC. CVET · Entity 123087 | GrantRestricted Stock Units · Derivative | 8,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001752836-21-000213 · wf-form4_162560179895275.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,275 Underlying: Common Stock · 8,275 shares Expires 2022-07-01 F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock or the cash value thereof. F2 · derivative.exercise_date: Subject to the Reporting Person's continuous service as a director of the Issuer, 100% of the RSUs will vest on the first anniversary of the grant date. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 00:31 UTC | Apellis Pharmaceuticals, Inc. APLS · Entity 47322 | GrantStock Option (Right to Buy) · Derivative | 27,600 | $0.00 Strike: $57.20 | $0.00 |
DisclosureSEC source: 0001127602-21-000261 · form4.xml · derivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,600 Underlying: Common Stock · 27,600 shares Expires 2030-12-31 F1 · derivative.exercise_date: This option was granted on 01/01/2021. The option vests quarterly over 1 year on the last day of each quarter from grant date. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:40 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126315 · a4.xml · derivative · entry 4 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,289 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:40 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 9,452 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126315 · a4.xml · derivative · entry 3 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,452 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:40 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126315 · a4.xml · derivative · entry 2 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:40 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerCommon Stock | 14,676 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126315 · a4.xml · nonDerivative · entry 1 FONTEYNE PAUL R. · CIK 0001727550 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.